75A50123C00010↗
Albert B. Sabin Vaccine Institute, Inc. (The) received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $163.08M obligated so far for health r&d services; health care - other; applied research. It runs to 2030-09-30.
Key facts · data as of Oct 25, 2026
- Recipient
- Albert B. Sabin Vaccine Institute, Inc. (The)
- Awarding agency
- Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Obligated to date
- $163.08M
- Potential value
- $240.94M
- Ends
- 2030-09-30
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 25, 2026.
Cite this page: SpendQuery, Award 75A50123C00010, data as of Oct 25, 2026, https://spendquery.com/award?id=CONT_AWD_75A50123C00010_7505_-NONE-_-NONE-
Albert B. Sabin Vaccine Institute, Inc. (The): all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys
THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI
Obligated to date$163.08M14 actions
Current value$163.08Mwith options exercised
Potential value$240.94Mif every option is used
Period2022-12-29 → 2030-09-30current end date
Passed on$28.58Mto 7 subcontractors
What it is
- Product or service
- Health R&D Services; Health Care - Other; Applied Research (PSC AN42)
- Industry
- Research and Development in Biotechnology (Except Nanobiotechnology) (NAICS 541714)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Competition
- Full and open competition · 1 offer received
- Pricing
- Cost plus fixed fee
- How it was bought
- Standalone contract
- Solicitation
- BAA18100SOL00003
- Where the work is
- District of Columbia, DC · district DC-98
Obligations by fiscal year
FY2023$71.39M
FY2024$17.03M
FY2025$70.39M
FY2026$4.27M
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
13 subawards totaling $28.58M (17.5% of what was obligated), as Albert B. Sabin Vaccine Institute, Inc. (The) reported them. Primes report subawards of $30,000 or more; smaller ones and unreported ones aren't here.
| Subcontractor | Amount | Subawards | Where | First | Last |
|---|---|---|---|---|---|
| Reithera S.R.L. | $24.59M | 4 | 2023-03-30 | 2024-11-04 | |
| Arranta Bio Ma LLC | $1.37M | 1 | MA | 2025-04-03 | 2025-04-03 |
| Bdo USA, P.C. | $796.0K | 2 | IL | 2023-03-30 | 2023-12-20 |
| Genie Biologic LTD | $731.5K | 2 | 2023-03-17 | 2023-09-27 | |
| Biologics Consulting Group, Inc. | $595.4K | 2 | VA | 2024-11-26 | 2025-02-17 |
| Balcary LTD | $458.5K | 1 | 2023-06-14 | 2023-06-14 | |
| Syneos Health LLC | $30.7K | 1 | NC | 2024-12-02 | 2024-12-02 |
The largest single subawards
| Date | To | Amount | For |
|---|---|---|---|
| 2023-03-30 | Reithera S.R.L. | $11.05M | BULK DRUG SUBSTANCE MANUFACTURING (SUDV) |
| 2023-10-13 | Reithera S.R.L. | $10.70M | BULK DRUG SUBSTANCE MANUFACTURING (MARV) |
| 2024-11-04 | Reithera S.R.L. | $2.37M | MARV OUTBREAK DRUG PRODUCT FILL FINISH |
| 2025-04-03 | Arranta Bio Ma LLC | $1.37M | DRUG PRODUCT FILL FINISH |
| 2024-09-27 | Reithera S.R.L. | $474.0K | SMALL SCALE FILL FINISH OF DRUG PRODUCT (SUDV) |
| 2023-06-14 | Balcary LTD | $458.5K | TECH TRANSFER CONSULTING SUPPORT |
| 2023-12-20 | Bdo USA, P.C. | $398.0K | MANUFACTURING BATCH RECORD REVIEW SUPPORT (MARV) |
| 2023-03-30 | Bdo USA, P.C. | $398.0K | BATCH RECORD DOCUMENTATION REVIEW SUPPORT (SUDV) |
| 2024-11-26 | Biologics Consulting Group, Inc. | $376.0K | PAI READINESS AND GAP ANALYSIS MARV |
| 2023-09-27 | Genie Biologic LTD | $365.8K | CMC CONSULTING MARV |
| 2023-03-17 | Genie Biologic LTD | $365.8K | CMC CONSULTING (SUDV) |
| 2025-02-17 | Biologics Consulting Group, Inc. | $219.4K | GAP ANALYSIS SUDV |
| 2024-12-02 | Syneos Health LLC | $30.7K | MANUFACTURING BATCH RECORD REVIEW SUPPORT FOR SUDV SMALL SCALE LOTS |
Every action
14 actions since 2022-12-29. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-05-11 | P00013 | Supplemental agreement (work within scope) | $4.27M | THE PURPOSE OF THIS MODIFICATION IS TO 1. OPTION 7 (CLIN 0008): DECREASE THE VALUE FROM $6,888,289.01 BY $1,713,590.57 TO $5,174,698.44. 2. OPTION 10 (CLIN 0011): INCREASE THE VALUE FROM $1,554,748.99 BY $1,713,590.57 TO $3,268,339.56. 3. OPTION 4 |
| 2025-07-29 | P00012 | Option exercised | $38.70M | THE PURPOSE OF THIS MODIFICATION IS TO 1. EXERCISE OPTION PERIOD 2 CLIN 0003 WITH A PERIOD OF PERFORMANCE OF JULY 22, 2025, TO DECEMBER 28, 2032, IN THE AMOUNT OF $38,697,183.73. AS A RESULT OF THIS MODIFICATION: 1. FUNDING IN THE AMOUNT OF $3 |
| 2025-07-08 | P00011 | Supplemental agreement (work within scope) | $1.55M | THE PURPOSE OF THIS MODIFICATION IS AS FOLLOWS: 1. CLIN 0008 (OPTION 7) THE TOTAL UNEXERCISED VALUE IS HEREBY DECREASED FROM $8,443,038.00 BY $1,554,748.99 TO $6,888,289.01 TO ACCOUNT FOR A DECREASE IN THE SCOPE OF WORK DUE TO THE SHORTER PERIOD OF |
| 2025-05-01 | P00010 | Supplemental agreement (work within scope) | $13.08M | THE PURPOSE OF THIS MODIFICATION IS AS FOLLOWS: 1. CLIN 0001/ BASE: INCREASE THE FUNDING FROM $52,015,534.00 BY $4,695,621.32 TO $56,711,155.32 TO FACILITATE THE ONSHORING OF FILLED DOSE STORAGE, AS WELL AS SUPPORT PROCESS DEVELOPMENT STUDIES AIMED |
| 2025-01-10 | P00009 | Supplemental agreement (work within scope) | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO DONATE 188 VIALS OF SUDV CLINICAL TRIAL MATERIAL FOR THREE NONCLINICAL STUDIES AS FOLLOWS: 1. CLIN 0001 (BASE PERIOD) - 188 VIALS TO BE DONATED IN ACCORDANCE WITH FAR 45.106 BROKEN DOWN AS FOLLOWS: A. |
| 2024-12-16 | P00008 | Supplemental agreement (work within scope) | $17.05M | THE PURPOSE OF THIS MODIFICATION IS HEREBY AMENDED AS FOLLOWS: 1. CLIN 0001 (BASE PERIOD) IS HEREBY AMENDED AS FOLLOWS: A. AN ADDITIONAL $17,053,156 IN FUNDS ARE BEING ALLOCATED TO ALLOW TO CONTINUE THE MANUFACTURING PROCESS DEVELOPMENT OF CHAD3-SU |
| 2024-10-10 | P00007 | Supplemental agreement (work within scope) | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO ADD AN AUDIT OF REITHERA SRL TO THE SCOPE OF CLIN 0005 AS FOLLOWS: 1. CLIN 0005 (OPTION 4) IS HEREBY AMENDED AS FOLLOWS: A. THE STATEMENT OF WORK IS HEREBY AMENDED TO REFLECT AN ONSITE AUDIT OF REITHER |
| 2024-09-25 | P00006 | Supplemental agreement (work within scope) | $17.03M | THE PURPOSE OF THIS MODIFICATION IS TO CHANGE PRODUCTION UNDER CLIN 0005 AND CLIN 0006 AND EXTEND THE PERIOD OF PERFORMANCE ON CLIN 0005 AS FOLLOWS: 1. CLIN 0005 (OPTION 4) IS HEREBY AMENDED AS FOLLOWS: A. ADDITIONAL PRODUCT DEVELOPMENT EFFORTS ARE |
| 2024-08-23 | P00005 | Supplemental agreement (work within scope) | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO INCORPORATE AN UPDATED STATEMENT OF WORK AMENDING THE VERBIAGE AS FOLLOWS: 1. CLIN 0001 IS HEREBY AMENDED PERFORM ACTIVITIES TO FILL-FINISH 2L OF SUDV DRUG PRODUCT AND DONATE THAT MATERIAL TO THE SABIN |
| 2024-07-16 | P00004 | Supplemental agreement (work within scope) | $0 | THE PURPOSE OF THIS $0 MODIFICATION IS TO: 1. CLIN 0001 IS HEREBY AMENDED TO INCLUDE AN ADDITIONAL 4TH DS BATCH RUN OF SUDV, AND TO REFLECT THE INCREASE OF REITHERA?S SUBCONTRACT BY $585,000 AT NO ADDITIONAL COST TO THE GOVERNMENT. 2. THIS REVISED |
| 2024-05-16 | P00003 | Administrative change | $0 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI |
| 2023-09-08 | P00002 | Administrative change | $0 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI |
| 2023-08-02 | P00001 | Option exercised | $36.43M | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI |
| 2022-12-29 | 0 | $34.96M | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-25). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗